Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
magazineClinigen soars on potential for large earnings boost
Clinigen (CLIN:AIM) 925P
Gain to date: 4.3%
Original entry point: Buy at 865p, 11 October 2018
Shares in pharma firm Clinigen (CLIN:AIM) have shot up after it agreed to buy the US rights to Novartis’ cancer drug Proleukin.
The deal, expected to complete in April, will enhance Clinigen’s profit in the current financial year ending 30 June and is forecast to boost group earnings per share by at least 25% next financial year.
Proleukin is now Clinigen’s biggest product and has the potential to significantly enhance earnings. The deal also means Clinigen has global rights to the drug, having bought the ex-US rights last summer.
The company is paying $120m, a further $60m in deferred payments one year after the transaction completes, and a possible $30m contingent on increased sales.
Numis analyst Stefan Hamill forecasts that Proleukin will increase earnings per share by 24% in the financial year to June 2021 and by 23% in the following year.
Following the acquisition, net debt-to-earnings before interest, tax, depreciation and amortisation at Clinigen is expected to rise to 2.4-times before falling to 2.0-times by the end of this year.
SHARES SAYS: Clinigen’s acquisition of Proleukin appears to be a wise strategic move that should support further growth for the company. Keep buying the shares.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Big News
- BHP, Royal Bank of Scotland, Reckitt Benckiser and other news
- Retail sales figures return to form in January
- Eyes on March update as dividend doubts beset SSE
- Global dividends expected to grow by 5.1% in 2019
- Is HSBC’s 6% yield enough compensation for disappointing results?
- Is the US about to deliver a growth shock?
